Have a feature idea you'd love to see implemented?
Let us know!
KZR Kezar Life Sciences Inc
Price (delayed)
$7.62
Market cap
$55.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$13.18
Enterprise value
$37.65M
Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule
Highlights
The debt has contracted by 14% YoY and by 4% from the previous quarter
The net income has contracted by 9% YoY but it has grown by 2.8% from the previous quarter
The EPS has declined by 8% year-on-year but it is up by 2.9% since the previous quarter
KZR's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Kezar Life Sciences's gross profit has shrunk by 100% QoQ and by 100% YoY
Key stats
What are the main financial stats of KZR
Market
Valuations
Earnings
Shares outstanding
7.3M
Market cap
$55.6M
Enterprise value
$37.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.41
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$94.18M
EBITDA
-$93.11M
Free cash flow
-$76.39M
Per share
Balance sheet
Liquidity
EPS
-$13.18
Free cash flow per share
-$10.47
Book value per share
$18.37
Revenue per share
$0
TBVPS
$22.49
Total assets
$164.09M
Total liabilities
$30.04M
Debt
$16.91M
Equity
$134.05M
Working capital
$135.95M
Debt to equity
0.13
Current ratio
7.65
Quick ratio
7.26
Net debt/EBITDA
0.19
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-50.1%
Return on equity
-59.7%
Return on invested capital
-59.5%
Return on capital employed
-65.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KZR stock price
How has the Kezar Life Sciences stock price performed over time
Intraday
1.74%
1 week
1.33%
1 month
-3.79%
1 year
-13.41%
YTD
-19.54%
QTD
-1.42%
Financial performance
How have Kezar Life Sciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$103.63M
Net income
-$95.78M
Gross margin
N/A
Net margin
N/A
KZR's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Kezar Life Sciences's gross profit has shrunk by 100% QoQ and by 100% YoY
The net income has contracted by 9% YoY but it has grown by 2.8% from the previous quarter
The company's operating income fell by 7% YoY but it rose by 3.3% QoQ
Growth
What is Kezar Life Sciences's growth rate over time
Valuation
What is Kezar Life Sciences stock price valuation
P/E
N/A
P/B
0.41
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 8% year-on-year but it is up by 2.9% since the previous quarter
The price to book (P/B) is 74% less than the 5-year quarterly average of 1.6 but 2.5% more than the last 4 quarters average of 0.4
KZR's equity is down by 38% year-on-year and by 11% since the previous quarter
KZR's revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Efficiency
How efficient is Kezar Life Sciences business performance
The company's return on invested capital has shrunk by 71% YoY and by 12% QoQ
KZR's ROE has shrunk by 65% YoY and by 10% QoQ
The return on assets has dropped by 57% year-on-year and by 8% since the previous quarter
Dividends
What is KZR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KZR.
Financial health
How did Kezar Life Sciences financials performed over time
The quick ratio fell by 46% YoY and by 23% QoQ
KZR's current ratio is down by 45% year-on-year and by 20% since the previous quarter
The debt is 87% less than the equity
KZR's debt to equity is up by 44% year-on-year and by 8% since the previous quarter
KZR's equity is down by 38% year-on-year and by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.